

7. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a light chain] containing the three light chain CDRs of antibody 11D10.

8. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a heavy chain] containing the three heavy chain CDRs of antibody 11D10.

9. (Amended) A [The isolated] polynucleotide according to [of] claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:2.

10. (Amended) A [The isolated] polynucleotide according to [of] claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:4.

11. (Amended) A [The isolated] polynucleotide according to [of] claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable region encoding sequence in SEQ ID NO:1.

12. (Amended) A [The isolated] polynucleotide according to [of] claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable region encoding sequence in SEQ ID NO:3.

14. (Amended) A[n isolated] polynucleotide comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:1, said region [capable of forming a stable duplex with a polynucleotide consisting of the light chain variable encoding sequence of SEQ ID NO:1 under hybridization conditions [where the region does not form a stable hybrid with SEQ ID NO:5 through SEQ ID NO:14] of 68°C and 0.15 M NaCl and 15 mM citrate buffer (1 X SSC).

15. (Amended) A [n isolated] polynucleotide comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:3, said region [capable of forming a stable duplex with a polynucleotide consisting of the heavy chain variable encoding sequence of SEQ ID NO:3 under hybridization conditions [where the region does not form a stable hybrid with SEQ ID NO:15 through SEQ ID NO:32] of 68°C and 0.15 M NaCl and 1.5 mM citrate buffer (1 X SSC).
C3

19. (Amended) A host cell comprising the polynucleotide of claim 6, wherein the polynucleotide is a recombinant polynucleotide.
C4

38. (Amended) A [pharmaceutical] composition comprising [an effective amount of] the polynucleotide of claim 6 and a pharmaceutically acceptable excipient.
C5

41. (Amended) An immunogenic composition [vaccine] comprising [an effective amount of] the polynucleotide of claim 6 in an amount sufficient to elicit an anti-HMFG immunological response and a pharmaceutically acceptable excipient.
C6

44. (Amended) The [vaccine] immunogenic composition of claim [38] 41, wherein the polynucleotide [vaccine immunogenic composition] is [comprises] comprised in a live virus or viral expression vector.
C7

45. (Amended) The [vaccine] immunogenic composition of claim 44, wherein the [vaccine] expression vector is vaccinia.

59. (New) The polynucleotide of claim 6, wherein antibody 11D10 has the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.
NE

7200. (New) A polynucleotide encoding an immunoglobulin variable region containing the three light chain CDRs in SEQ ID NO:2.
*RECEIVED
JUN 30 2000
TECHNICON INSTRUMENTS CORPORATION*

OK to enter Amst 2 AE 73
61. (New) A polynucleotide encoding an immunoglobulin variable region containing the three heavy chain CDRs in SEQ ID NO:4.

M G
62. (New) A polynucleotide according to claim 6, wherein the anti-HMFG immunological response comprises production of anti-HMFG antibody by the mammal.

M G
63. (New) A polynucleotide according to claim 6, wherein the anti-HMFG immunological response comprises production of anti-HMFG reactive T cells by the mammal.

M G
64. (New) A polynucleotide according to claim 6, encoding both an immunoglobulin variable region containing the three light chain CDRs of antibody 11D10 and an immunoglobulin variable region containing the three heavy chain CDRs of antibody 11D10.

M G
65. (New) A polynucleotide according to claim 64, wherein the variable regions are joined by a linker polypeptide of about 5 to 20 amino acids.

M G
66. (New) The immunogenic composition of claim 41, which is sterile.

67. (New) A method of preparing a polypeptide capable of eliciting an anti-HMFG immunological response in a mammal, comprising expressing the polynucleotide of claim 6 in a host cell.

D
68. (New) A method of preparing a light chain variable region of antibody 11D10 comprising expressing the polynucleotide of claim 6 in a host cell.

D
Ante F12
69. (New) A method of preparing a heavy chain variable region of antibody 11D10 comprising variable region of antibody 11D10 comprising expressing the polynucleotide of claim 6 in a host cell.

Ante F13
70. (New) A kit for eliciting an anti-HMFG immunological response in a mammal comprising the polynucleotide of claim 6 in suitable packaging.